MeiraGTx Holdings plc
MGTX
Rank in Stocks
#9098
MeiraGTx Holdings plc operates as a clinical-stage gene therapy company,... MeiraGTx Holdings plc operates as a clinical-stage gene therapy company, dedicated to pioneering therapeutic solutions for individuals afflicted by serious illnesses. Its development efforts span a broad spectrum of conditions, encompassing ocular diseases like inherited forms of blindness, as well as xerostomia (dry mouth) that often follows radiation treatment for head and neck cancers. The company also targets various degenerative and neurodegenerative disorders, notably amyotrophic lateral sclerosis (ALS) and Parkinson's disease. Currently, several of its programs are in active clinical development, including Phase 1/2 trials for Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, radiation-induced Xerostomia, and Parkinson's. MeiraGTx is also preparing to commence a clinical program for xerostomia linked to Sjogren's syndrome and maintains preclinical initiatives for other neurodegenerative conditions. A key collaboration exists with Janssen Pharmaceuticals, Inc. to advance regulatable gene therapy treatments, leveraging MeiraGTx's proprietary riboswitch technology. Established in 2015, MeiraGTx Holdings plc is headquartered in New York, New York.
Share Price
$9.49
Last synced: 2026-11-09
Market Cap
$911.45M
Change (1 day)
5.44%
Change (1 year)
6.63%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade MeiraGTx Holdings plc (MGTX)
Category
Healthcare
EPS for MeiraGTx Holdings plc (MGTX)
EPS as of June 2026 TTM: $0.76
According to MeiraGTx Holdings plc's latest financial reports, its current EPS (TTM) is $0.76. At the end of 2025 the company had an EPS of $-1.42, an increase over its 2024 EPS of $-2.12.
EPS history for MeiraGTx Holdings plc from 2016 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $0.76 | -153.52% |
| 2025 | $-1.42 | -33.02% |
| 2024 | $-2.12 | 42.28% |
| 2023 | $-1.49 | -48.08% |
| 2022 | $-2.87 | 59.44% |
| 2021 | $-1.80 | 25.87% |
| 2020 | $-1.43 | -9.49% |
| 2019 | $-1.58 | -63.84% |
| 2018 | $-4.37 | 20.72% |
| 2017 | $-3.62 | 258.42% |
| 2016 | $-1.01 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | 1,960.53% |
US
|
|
| $-7.07 | -1,030.26% |
US
|
|
| $-5.29 | -796.05% |
AU
|
|
| $12.88 | 1,594.75% |
BE
|
|
| $21.56 | 2,736.84% |
NL
|
Questions about MeiraGTx Holdings plc's earnings per share (EPS)
What is MeiraGTx Holdings plc's earnings per share (EPS)?
MeiraGTx Holdings plc's earnings per share (EPS) over the last twelve months is $0.76, as of Jun 2026.
What was MeiraGTx Holdings plc's earnings per share (EPS) in 2025?
In 2025, MeiraGTx Holdings plc's earnings per share (EPS) was $-1.42, compared with $-2.12 in 2024.
How has MeiraGTx Holdings plc's earnings per share (EPS) changed since 2020?
From 2020 to 2025, MeiraGTx Holdings plc's earnings per share (EPS) was highest in 2025 ($-1.42) and lowest in 2022 ($-2.87).
How does MeiraGTx Holdings plc's earnings per share (EPS) compare with similar companies?
MeiraGTx Holdings plc's earnings per share (EPS) ($0.76) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.